Search - tctmd.com

Displaying 561 - 580 of 2268

Sort: Relevancy | Date

News Daily News

Less Occlusion, Hematomas With Distal Radial Access: Meta-analysis

Michael O'Riordan

November 22, 2022

News Daily News

Left-Sided Bioprosthetic Valves Often Dysfunctional in Pregnant Women

L.A. McKeown

November 21, 2022

News Conference News

Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices

L.A. McKeown

November 18, 2022

News Daily News

Age-Related Macular Degeneration Linked to Severe Vascular Disease

Caitlin E. Cox

November 18, 2022

News Daily News

New Risk Models Superior to Pretest Probability at Predicting CAD

Yael L. Maxwell

November 15, 2022

News Daily News

Many STEMI Patients Not Treated Within National Time Goals

Michael O'Riordan

November 15, 2022

News Conference News AHA 2022

‘Agnostic’ EHR Alerts Boost VTE Prophylaxis in Hospitals and Postdischarge

L.A. McKeown

November 11, 2022

News Conference News AHA 2022

Partial Oral Antibiotic Regimen for Endocarditis Effective in Real World

Michael O'Riordan

November 10, 2022

News Conference News AHA 2022

RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl

Todd Neale

November 10, 2022

News Conference News AHA 2022

Endothelin Receptor Antagonist Effective in Resistant Hypertension: PRECISION

Michael O'Riordan

November 09, 2022

News Daily News

Heart Risks Higher With Moderna vs Pfizer/BioNTech Shot, Direct Comparison Shows

Caitlin E. Cox

November 09, 2022

News Conference News AHA 2022

China Rural Intervention Still Reaping BP Control Wins at 3 Years

L.A. McKeown

November 09, 2022

News Conference News AHA 2022

SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint

Todd Neale

November 09, 2022

News Conference News AHA 2022

Four Drugs, One Pill: QUARTET USA Supports New Strategy for BP-Lowering

Caitlin E. Cox

November 08, 2022

News Conference News AHA 2022

Big Drops in Blood Pressure With Baxdrostat: BrigHTN Phase II Study

Michael O'Riordan

November 07, 2022

News Conference News AHA 2022

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

L.A. McKeown

November 07, 2022

News Conference News AHA 2022

In High BP, Chlorthalidone and Hydrochlorothiazide Have Similar Impact on MACE

Todd Neale

November 05, 2022

News Conference News AHA 2022

High-Sensitivity Troponin Testing on the Rise in the US but Still Limited

Michael O'Riordan

November 04, 2022

News Conference News VIVA 2022

‘Heartless’ Indifference Drives PAD/CLTI Amputations in Underserved Groups

L.A. McKeown

November 04, 2022

News Conference News VIVA 2022

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

L.A. McKeown

November 03, 2022

Advertisement

Less Occlusion, Hematomas With Distal Radial Access: Meta-analysis

Left-Sided Bioprosthetic Valves Often Dysfunctional in Pregnant Women

Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices

Age-Related Macular Degeneration Linked to Severe Vascular Disease

New Risk Models Superior to Pretest Probability at Predicting CAD

Many STEMI Patients Not Treated Within National Time Goals

‘Agnostic’ EHR Alerts Boost VTE Prophylaxis in Hospitals and Postdischarge

Partial Oral Antibiotic Regimen for Endocarditis Effective in Real World

RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl

Endothelin Receptor Antagonist Effective in Resistant Hypertension: PRECISION

Heart Risks Higher With Moderna vs Pfizer/BioNTech Shot, Direct Comparison Shows

China Rural Intervention Still Reaping BP Control Wins at 3 Years

SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint

Four Drugs, One Pill: QUARTET USA Supports New Strategy for BP-Lowering

Big Drops in Blood Pressure With Baxdrostat: BrigHTN Phase II Study

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

In High BP, Chlorthalidone and Hydrochlorothiazide Have Similar Impact on MACE

High-Sensitivity Troponin Testing on the Rise in the US but Still Limited

‘Heartless’ Indifference Drives PAD/CLTI Amputations in Underserved Groups

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content